Comparative Study of 18F-FDG PET/CT Metabolic Alteration Patterns in Cerebral Amyloid Angiopathy and Alzheimer's Disease
-
摘要:
目的 比较脑淀粉样血管病(cerebral amyloid angiopathy,CAA)与阿尔茨海默病(Alzheimer's disease,AD)患者的脑代谢差异,评价18F-脱氧葡萄糖(fluorodeoxy glucose,FDG)正电子发射断层显像/计算机体层成像(positron emission tomography/computed tomography, PET/CT)脑显像对CAA和AD的鉴别价值。 方法 回顾性纳入2020年12月至2021年6月北京协和医院符合修订Boston标准的很可能CAA患者以及年龄与其相近的AD患者。随机纳入同期行18F-FDG PET/CT检查且认知功能正常的人群为对照。对3组18F-FDG PET/CT图像进行视觉分析和定量分析。 结果 共入选符合纳入和排除标准的10例很可能CAA患者(CAA组)、10例AD患者(AD组)以及11例认知功能正常的对照人群(对照组)。视觉分析结果显示,相较对照组,AD组典型表现为双侧基本对称的颞顶叶代谢减低,以颞叶内侧、后扣带回代谢减低最为显著;CAA组皮层代谢减低区呈无特定规律分布,代谢减低或缺损区与出血区域相关。基于体素的脑代谢图像定量分析结果显示,相较对照组,AD组后扣带回、海马旁回、顶叶、颞叶内侧的代谢显著减低(P < 0.01);CAA组广泛白质区以及尾状核头、胼胝体、前扣带回、颞叶外侧皮层等处代谢显著减低(P < 0.01)。基于脑区的定量分析显示,CAA组枕叶/后扣带回(occipital/posterior cingulate, O/PC)相对脑桥的18F-FDG标准摄取值比值(standardized uptake value ratio,SUVr)明显低于AD组(0.91±0.05比1.07±0.08,P < 0.001);O/PC SUVr鉴别很可能CAA、AD的曲线下面积为0.98(95%CI:0.93~1.00),最佳临界值为0.96,灵敏度为100%,特异度为90%。 结论 CAA与AD患者的18F-FDG PET/CT显像呈明显不同的代谢降低图型;O/PC SUVr或可作为二者鉴别诊断的敏感指标。 -
关键词:
- 脑淀粉样血管病 /
- 阿尔茨海默病 /
- 18F-脱氧葡萄糖 /
- 正电子发射断层显像/计算机体层成像
Abstract:Objective To compare the metabolism pattern of the brain in patients with cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD), and to evaluate the value of brain imaging of 18F-fluorodeoxy glucose (FDG) positron emission tomography/computed tomography (PET/CT) in differentiating CAA and AD. Methods We retrospectively recruited patients with probable CAA (revised Boston diagnostic criteria) and AD of similar age from December 2020 to June 2021 at Peking Union Medical College Hospital. Patients with normal cognition that underwent 18F-FDG PET/CT during the same period were randomly included as controls. We performed visual analysis and quantitative analysis of PET/CT imaging in the three groups. Results Ten patients with probable CAA (CAA group), 10 patients with AD (AD group), and 11 control subjects with normal cognitive function (control group) that met the inclusion and exclusion criteria were enrolled. Visual analysis showed that, compared with the control group, the AD group showed mostly bilateral symmetrical hypometabolism in temporoparietal lobes, with the most significant hypometabolism in the medial temporal lobe and posterior cingulate gyrus; the CAA group exhibited unspecific cortical hypometabolic areas corresponding to hemorrhage. Quantitative analysis of voxel-based brain metabolism images showed that metabolism in the posterior cingulate gyrus, parahippocampal gyrus, parietal lobe, and medial temporal lobe was significantly reduced in the AD group compared with the control group (P < 0.01); metabolism was significantly reduced in the extensive white matter areas, as well as in the caudate nucleus head, corpus callosum, anterior cingulate gyrus, and lateral temporal cortex in the CAA group (P < 0.01). Quantitative analysis based on brain regions showed that the standardized uptake value ratio (SUVr) of 18F-FDG in the occipital/posterior cingulate (O/PC) was significantly lower in the CAA group than in the AD group (0.91±0.05 vs. 1.07±0.08, P < 0.001); the area under the curve for O/PC SUVr identification of probable CAA and AD was 0.98 (95% CI: 0.93-1.00), with an optimal threshold of 0.96, exhibiting sensitivity of 100% and specificity of 90%. Conclusions Probable CAA and AD patients exhibited distinct brain hypometabolism patterns. O/PC SUVr can be a sensitive indicator for differential diagnosis between CAA and AD. 作者贡献:贾琛皓、吴美其负责研究设计、数据分析、论文撰写与修订;郭瑞杰负责影像资料收集;倪俊负责临床资料收集、数据分析;崔瑞雪负责指导研究设计、数据审核及论文审校。利益冲突:所有作者均声明不存在利益冲突 -
图 1 75岁女性AD患者,进行性记忆力下降4年余,伴精神、行为异常,MMSE评分19分,18F-FDG PET/CT示后扣带回、双侧颞叶内侧代谢对称性减低(A、B,箭头),18F-AV45 PET/CT示大脑皮质Aβ弥漫沉积(C),头颅SWI未发现皮层或皮层下明确微出血灶(D);58岁男性很可能CAA患者,进行性反应力、记忆力下降5年余,双下肢乏力、行走变慢3年余,MMSE评分29分,18F-FDG PET/CT示后扣带回代谢保留、双侧颞叶内侧代谢略低(E、F,箭头),余皮层呈无规律、不均匀、不对称多处代谢减低,18F-AV45 PET/CT示大脑皮质Aβ弥漫沉积(G),头颅SWI示双侧大脑半球皮层及皮层下多发微出血灶(H)
AD:阿尔茨海默病;CAA:脑淀粉样血管病;18F-FDG:18F-脱氧葡萄糖;PET/CT:正电子发射断层显像/计算机体层成像;MMSE:简易精神状态检查量表;SWI:磁敏感加权成像
图 2 AD和很可能CAA患者基于体素的脑代谢改变图像
A. AD患者颞叶内侧(红箭头)、后扣带回(蓝箭头)和顶叶背外侧皮层(白箭头)代谢减低;B.很可能CAA患者广泛白质区、尾状核头(红箭头)、胼胝体(蓝箭头)、前扣带回(蓝箭头)、颞叶外侧皮层(白箭头)代谢减低
AD、CAA:同图 1图 3 O/PC SUVr鉴别AD与很可能CAA的ROC曲线图
AD、CAA: 同图 1;O/PC: 枕叶/后扣带回;SUVr: 标准摄取值比值;ROC: 操作者工作特征
-
[1] Boulouis G, Charidimou A, Greenberg SM. Sporadic Cerebral Amyloid Angiopathy: Pathophysiology, Neuroimag-ing Features, and Clinical Implications[J]. Semin Neurol, 2016, 36: 233-243. doi: 10.1055/s-0036-1581993 [2] Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy[J]. Brain, 2017, 140: 1829-1850. doi: 10.1093/brain/awx047 [3] Akers C, Acosta LMY, Considine C, et al. Atypical Clinical Manifestations of Cerebral Amyloid Angiopathy[J]. Curr Neurol Neurosci Rep, 2019, 19: 64. doi: 10.1007/s11910-019-0981-4 [4] Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy[J]. Neurology, 2010, 74: 1346-1350. doi: 10.1212/WNL.0b013e3181dad605 [5] Greenberg SM, Charidimou A. Diagnosis of Cerebral Amy-loid Angiopathy: Evolution of the Boston Criteria[J]. Stroke, 2018, 49: 491-497. doi: 10.1161/STROKEAHA.117.016990 [6] Charidimou A, Farid K, Baron JC. Amyloid-PET in sporadic cerebral amyloid angiopathy: A diagnostic accuracy meta-analysis[J]. Neurology, 2017, 89: 1490-1498. doi: 10.1212/WNL.0000000000004539 [7] Charidimou A, Farid K, Tsai HH, et al. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance[J]. J Neurol Neurosurg Psychiatry, 2018, 89: 410-417. doi: 10.1136/jnnp-2017-316851 [8] Farid K, Charidimou A, Baron JC. Amyloid positron emis-sion tomography in sporadic cerebral amyloid angiopathy: A systematic critical update[J]. Neuroimage Clin, 2017, 15: 247-263. doi: 10.1016/j.nicl.2017.05.002 [9] Planton M, Saint-Aubert L, Raposo N, et al. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study[J]. J Alzheimers Dis, 2020, 73: 1607-1614. doi: 10.3233/JAD-190625 [10] Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impair-ment, Alzheimer's disease, and other dementias[J]. J Nucl Med, 2008, 49: 390-398. doi: 10.2967/jnumed.107.045385 [11] Smailagic N, Vacante M, Hyde C, et al. 18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)[J]. Cochrane Database Syst Rev, 2015, 1: Cd010632. [12] Kantarci K, Boeve BF, Przybelski SA, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prod-romal AD[J]. Neuroimage Clin, 2021, 31: 102754. doi: 10.1016/j.nicl.2021.102754 [13] Arbizu J, Festari C, Altomare D, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 1497-1508. doi: 10.1007/s00259-018-4039-7 [14] Bergeret S, Queneau M, Rodallec M, et al. Brain Glucose Metabolism in Cerebral Amyloid Angiopathy: An FDG-PET Study[J]. Stroke, 2021, 52: 1478-1482. doi: 10.1161/STROKEAHA.120.032905 [15] Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13: 614-629. doi: 10.1016/S1474-4422(14)70090-0 [16] Bergeret S, Queneau M, Rodallec M, et al. [(18) F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease[J]. Eur J Neurol, 2021, 28: 1511-1519. doi: 10.1111/ene.14743 [17] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease[J]. Lancet, 2021, 397: 1577-1590. doi: 10.1016/S0140-6736(20)32205-4 [18] Gatti L, Tinelli F, Scelzo E, et al. Understanding the Pathophysiology of Cerebral Amyloid Angiopathy[J]. Int J Mol Sci, 2020, 21: 3435. doi: 10.3390/ijms21103435 [19] Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly[J]. Ann Neurol, 2011, 70: 871-880. doi: 10.1002/ana.22516 [20] Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. Ⅱ. The distribution of amyloid vascular changes[J]. Stroke, 1983, 14: 924-928. doi: 10.1161/01.STR.14.6.924 [21] Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review[J]. BMC Neurol, 2009, 9: 3. doi: 10.1186/1471-2377-9-3 [22] Samuraki M, Matsunari I, Yoshita M, et al. Cerebral Amyloid Angiopathy-Related Microbleeds Correlate with Glucose Metabolism and Brain Volume in Alzheimer's Disease[J]. J Alzheimers Dis, 2015, 48: 517-528. doi: 10.3233/JAD-150274 [23] Farid K, Hong YT, Aigbirhio FI, et al. Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value?[J]. PLoS One, 2015, 10: e0139926. doi: 10.1371/journal.pone.0139926 [24] Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers[J]. Lancet Neurol, 2017, 16: 661-676. doi: 10.1016/S1474-4422(17)30159-X [25] Tomonaga M. Cerebral amyloid angiopathy in the elderly[J]. J Am Geriatr Soc, 1981, 29: 151-157. doi: 10.1111/j.1532-5415.1981.tb01757.x